<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081143</url>
  </required_header>
  <id_info>
    <org_study_id>RAMIRIS</org_study_id>
    <secondary_id>AIO-STO-0415</secondary_id>
    <nct_id>NCT03081143</nct_id>
  </id_info>
  <brief_title>Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy</brief_title>
  <acronym>RAMIRIS</acronym>
  <official_title>Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will evaluate whether it is beneficial in terms of prolongation of&#xD;
      survival to combine FOLFIRI (standard treatment) with ramucirumab compared to the standard&#xD;
      treatment of ramucirumab plus paclitaxel in patients with advanced gastric cancer after&#xD;
      failure of one prior line of palliative chemotherapy. This trial aims to investigate the&#xD;
      efficacy and safety of ramucirumab plus FOLFIRI (investigational arm A) compared to&#xD;
      paclitaxel plus ramucirumab (control arm B).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS Rate at 6 months primary endpoint for phase II</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>OS Rate at 6 months is defined at the proportion of patients being known to be alive at 6 months after randomisation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival (OS) co-primary endpoint for phase III</measure>
    <time_frame>from date of randomization to 1 year after end of treatment</time_frame>
    <description>duration from date of randomization to death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Overall Response Rate (ORR) co-primary endpoint for phase III</measure>
    <time_frame>from randomization for the time of treatment with a maximum of 1 year</time_frame>
    <description>proportion of patients with complete or partial response (CR + PR) according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from date of first study drug administration to up to 1 year after study completion</time_frame>
    <description>duration from the first study drug administration to the first documented evidence of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (CR + PR) - endpoint for phase II</measure>
    <time_frame>from randomization for the time of treatment with a maximum of 1 year</time_frame>
    <description>proportion of patients with complete or partial response (CR + PR) according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (CR + PR + SD)</measure>
    <time_frame>from randomization for the time of treatment with a maximum of 1 year</time_frame>
    <description>proportion of patients with complete or partial response or stable disease (CR + PR + SD) according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of adverse events according to CTC criteria</measure>
    <time_frame>from randomization until 30 days after the last dose of study drug</time_frame>
    <description>incidence and severity of adverse events according to CTC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes: quality of life according to questionnaire EORTC-QLQ-C30</measure>
    <time_frame>from randomization until 30 days after the last dose of study drug</time_frame>
    <description>quality of life scores according to validated questionnaire EORTC-QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">429</enrollment>
  <condition>Advanced Gastric or EGJ Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI plus Ramucirumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel plus Ramucirumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle</description>
    <arm_group_label>FOLFIRI plus Ramucirumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle</description>
    <arm_group_label>FOLFIRI plus Ramucirumab</arm_group_label>
    <arm_group_label>Paclitaxel plus Ramucirumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m2 on day 1, 8, 15</description>
    <arm_group_label>Paclitaxel plus Ramucirumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Male or female* ≥ 18 years of age; Patients in reproductive age must be willing to use&#xD;
             adequate contraception (that results in a failure rate of &lt;1% per year) during the&#xD;
             study and for 3 months after the end of ramucirumab treatment (appropriate&#xD;
             contraception is defined as surgical sterilization (e.g. bilateral tubal ligation,&#xD;
             vasectomy), hormonal contraception (including oral contraceptive pills (combination of&#xD;
             estrogen and progesterone), vaginal ring, injectables, implants, intrauterine devices&#xD;
             (IUDs) and intrauterine hormone-releasing system (IUS)), nonhormonal IUDs and complete&#xD;
             abstinence). Female patients with childbearing potential need to have a negative&#xD;
             pregnancy test within 7 days before study start.&#xD;
&#xD;
          3. Histologically proven gastric adenocarcinoma including adenocarcinoma of the&#xD;
             esophagogastric junction&#xD;
&#xD;
          4. Metastatic or locally advanced disease, not amenable to potentially curative resection&#xD;
&#xD;
          5. Phase II only: Documented objective radiological or clinical disease progression&#xD;
             during or within 6 months of the last dose of first-line platinum and fluoropyrimidine&#xD;
             doublet with or without anthracycline or docetaxel. Neoadjuvant/adjuvant treatment is&#xD;
             not counted unless progression occurs &lt;6 months after completion of the treatment. In&#xD;
             these cases neoadjuvant/adjuvant treatment is counted as one line.&#xD;
&#xD;
             OR Phase III only: Radiological or clinical disease progression during or after the&#xD;
             last dose of a first-line platinum, fluoropyrimidine-containing therapy. Patients must&#xD;
             also have received a taxane with the first-line or during their adjuvant or&#xD;
             neoadjuvant therapy or both. Neoadjuvant/adjuvant platinum containing therapy is&#xD;
             permitted and is counted as first-line therapy if progression occurs &lt;12 months after&#xD;
             completion of the treatment. If progression occurred ≥ 12 months after completion of&#xD;
             neoadjuvant/adjuvant therapy, the therapy is not counted as a treatment line. At&#xD;
             decision of the investigator, different regimens can be considered as one line of&#xD;
             prior treatment, in case these were administrated as a sequential or alternating&#xD;
             therapy.&#xD;
&#xD;
          6. Measurable or non-measurable but evaluable disease&#xD;
&#xD;
          7. ECOG performance status 0-1&#xD;
&#xD;
          8. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          9. Adequate hematological, hepatic and renal functions:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL (5.58 mmol/L)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times the upper normal limit (UNL)&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL in absence of liver metastases, or ≤ 5 x&#xD;
                  UNL in presence of liver metastases; AP ≤ 5 x UNL&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal, or creatinine clearance (measured&#xD;
                  via 24-hour urine collection) ≥40 mL/minute (that is, if serum creatinine is &gt;1.5&#xD;
                  times the ULN, a 24-hour urine collection to calculate creatinine clearance must&#xD;
                  be performed)&#xD;
&#xD;
               -  Urinary protein ≤1+ on dipstick or routine urinalysis (UA; if urine dipstick or&#xD;
                  routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate&#xD;
                  &lt;1000 mg of protein in 24 hours to allow participation in this protocol)&#xD;
&#xD;
               -  Adequate coagulation function as defined by International Normalized Ratio (INR)&#xD;
                  ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless&#xD;
                  receiving anticoagulation therapy). Patients receiving warfarin/ phenprocoumon&#xD;
                  must be switched to low molecular weight heparin and have achieved stable&#xD;
                  coagulation profile prior to first dose of protocol therapy.&#xD;
&#xD;
         10. Ability to comply with scheduled assessments and with management of toxicities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other tumor type than adenocarcinoma (e.g. leiomyosarcoma, lymphoma) or a second&#xD;
             cancer except in patients with squamous or basal cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix that has been effectively treated. Patients curatively&#xD;
             treated and disease-free for at least 5 years will be discussed with the sponsor&#xD;
             before inclusion&#xD;
&#xD;
          2. Squamous gastric cancer&#xD;
&#xD;
          3. Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
             indicated in the study protocol&#xD;
&#xD;
          4. Phase II only: Previous therapy with paclitaxel or FOLFIRI Phase III only: Previous&#xD;
             therapy with FOLFIRI&#xD;
&#xD;
          5. Current treatment with any anti-cancer therapy ≤ 2 weeks prior to study treatment&#xD;
             start unless rapidly progressing disease is measured&#xD;
&#xD;
          6. Concurrent treatment with any other anti-cancer therapy&#xD;
&#xD;
          7. Previous exposure to a VEGF or VEGFR inhibitor or any antiangiogenic agent, or prior&#xD;
             enrolment in this study&#xD;
&#xD;
          8. Patient has undergone major surgery within 28 days prior to first dose of protocol&#xD;
             therapy, or minor surgery/subcutaneous venous access device placement within 7 days&#xD;
             prior to first dose of protocol therapy. The patient has elective or planned major&#xD;
             surgery to be performed during the course of the clinical trial&#xD;
&#xD;
          9. Grade 3-4 GI bleeding within 3 months prior to enrollment&#xD;
&#xD;
         10. History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other&#xD;
             significant thromboembolism (venous port or catheter thrombosis or superficial venous&#xD;
             thrombosis are not considered &quot;significant&quot;) during the 3 months prior to first dose&#xD;
             of protocol therapy&#xD;
&#xD;
         11. Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a&#xD;
             history of hepatic encephalopathy or clinically meaningful ascites resulting from&#xD;
             cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis&#xD;
             requiring diuretics or paracentesis.&#xD;
&#xD;
         12. Known brain or leptomeningeal metastases&#xD;
&#xD;
         13. Known allergic/ hypersensitivity reaction to any of the components of the treatment&#xD;
&#xD;
         14. Contraindications to the use of atropine&#xD;
&#xD;
         15. Other serious illness or medical conditions within the last 12 months prior to study&#xD;
             drug administration&#xD;
&#xD;
         16. Any arterial thromboembolic events, including but not limited to myocardial&#xD;
             infarction, transient ischemic attack, cerebrovascular accident, or unstable angina,&#xD;
             within 6 months prior to first dose of protocol&#xD;
&#xD;
         17. The patient has uncontrolled or poorly-controlled hypertension (&gt;160 mmHg systolic or&#xD;
             &gt; 100 mmHg diastolic for &gt;4 weeks) despite standard medical management&#xD;
&#xD;
         18. Active uncontrolled infection&#xD;
&#xD;
         19. Current history of chronic diarrhea&#xD;
&#xD;
         20. Active disseminated intravascular coagulation&#xD;
&#xD;
         21. Any other serious concomitant disease or medical condition that in the judgment of the&#xD;
             investigator renders the subject at high risk of treatment complication or reduced the&#xD;
             probability of assessing clinical effect&#xD;
&#xD;
         22. Known Dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
         23. Prior history of GI perforation/fistula (within 6 months of first dose of protocol&#xD;
             therapy) or risk factors for perforation.&#xD;
&#xD;
         24. Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first&#xD;
             dose of protocol therapy&#xD;
&#xD;
         25. The patient is receiving chronic antiplatelet therapy, including aspirin, nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others),&#xD;
             dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose&#xD;
             325 mg/day) is permitted&#xD;
&#xD;
         26. Concurrent treatment with other experimental drugs or participation in another&#xD;
             clinical trial with any investigational drug within 30 days prior to treatment start&#xD;
             or at the same time as this study&#xD;
&#xD;
         27. Lack of resolution of all toxic effects (excluding alopecia) of prior chemotherapy,&#xD;
             prior radiotherapy or surgical procedure to National Cancer Institute (NCI) Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) grade &lt; 1. Note: Neuropathy due to&#xD;
             prior chemotherapy is allowed if not &gt; NCI Grade II according to CTCAE version 4.03&#xD;
&#xD;
         28. Subject pregnant or breast feeding, or planning to become pregnant within 3 months&#xD;
             after the end of treatment&#xD;
&#xD;
         29. Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standardCTFG-Guideline) during treatment and for 3&#xD;
             months (male or female) after the end of treatment&#xD;
&#xD;
         30. Patients known to have a HER 2 positive Cancer who have not been treated already with&#xD;
             a HER 2 targeting agent.&#xD;
&#xD;
         31. Patients with a psychiatric illness or patients imprisoned or working in the&#xD;
             institution of the treating physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie Lorenzen, Prof.</last_name>
    <phone>089 /4140-9696</phone>
    <email>sylvie.lorenzen@mri.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Pauligk</last_name>
    <phone>+496976014420</phone>
    <email>pauligk.claudia@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Thuss-Patience</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin Buch</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Reichardt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld Mitte</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Probst</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Stahl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salah-Eddin Al-Batran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Praxis Eppendorf (HOPE)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eray Gökkurt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum</name>
      <address>
        <city>Lahr</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Charles Moulin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäres Krebszentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Lordick</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Lorenzen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Georg Kopp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ettrich</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

